What's New for Vol. 40, Supp. 03
Changes to patent and exclusivity information

Patents whose numbers are in italics have been extended under 35 USC 156. All expiration dates include applicable Sec. 156 and pediatric (PED) extensions.

The "[Img]" link takes you to the patent image at the EPO. However, please note that the EPO does not include Certificates of Correction.


AIRDUO DIGIHALER (POWDER) (INHALATION) FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE
Drug Classes: corticosteroid; beta-2 adrenergic agonist
NDA Applicant: TEVA PHARM      NDA No.: 208799  Prod. No.: 004 RX (0.055MG/INH;EQ 0.014MG BASE/INH); 005 RX (0.113MG/INH;EQ 0.014MG BASE/INH); 006 RX (0.232MG/INH;EQ 0.014MG BASE/INH)
PatentsExpirationChange
Pat. No. 10561808 [Img]
Dose counter for inhaler having an anti-reverse rotation actuator
Pat. Sub. Date(s): All strengths: Mar 19, 2020
Claim Types: Part of a dosage form
Jan 1, 2032New patent for this product
Pat. No. 10569034 [Img]
Compliance monitoring module for a breath-actuated inhaler
Pat. Sub. Date(s): All strengths: Mar 12, 2020
Claim Types: Device; Method of administration
Aug 16, 2036New patent for this product

ALECENSA (CAPSULE) (ORAL) ALECTINIB HYDROCHLORIDE
Drug Classes: kinase inhibitor
NDA Applicant: HOFFMANN-LA ROCHE      NDA No.: 208434  Prod. No.: 001 RX (EQ 150MG BASE)
PatentsExpirationChange
Pat. No. 10350214 [Img]
Preparation containing tetracyclic compound at high dose
Pat. Sub. Date(s): 001: Mar 9, 2020
Claim Types: Formulation; Process
Apr 24, 2035New patent for this product

ARMONAIR RESPICLICK (POWDER) (INHALATION) FLUTICASONE PROPIONATE
Drug Classes: corticosteroid
NDA Applicant: TEVA PHARM      NDA No.: 208798  Prod. No.: 001 DISC (0.055MG/INH); 002 DISC (0.113MG/INH); 003 DISC (0.232MG/INH)
PatentsExpirationChange
Pat. No. 10561808 [Img]
Dose counter for inhaler having an anti-reverse rotation actuator
Pat. Sub. Date(s): All strengths: Mar 19, 2020
Claim Types: Part of a dosage form
Jan 1, 2032New patent for this product

BARHEMSYS (SOLUTION) (INTRAVENOUS) AMISULPRIDE
NDA Applicant: ACACIA PHARMA LTD      NDA No.: 209510  Prod. No.: 001 RX (5MG/2ML (2.5MG/ML))
PatentsExpirationChange
Pat. No. 9084765 [Img]
Use of amisulpride as an anti-emetic
Pat. Sub. Date(s): 001: Mar 16, 2020
Claim Types: Method of use
Use Code: U-1744: Prevention of post-operative nausea and vomiting
Use Code: U-2754: Treatment of post-operative nausea and vomiting
Mar 10, 2031New patent for this product
Pat. No. 9545426 [Img]
Use of amisulpride as an anti-emetic
Pat. Sub. Date(s): 001: Mar 16, 2020
Claim Types: Method of use
Use Code: U-1744: Prevention of post-operative nausea and vomiting
Use Code: U-2754: Treatment of post-operative nausea and vomiting
Mar 10, 2031New patent for this product
Pat. No. 9889118 [Img]
Use of amisulpride as an anti-emetic
Pat. Sub. Date(s): 001: Mar 16, 2020
Claim Types: Method of use
Use Code: U-1744: Prevention of post-operative nausea and vomiting
Use Code: U-2754: Treatment of post-operative nausea and vomiting
Mar 10, 2031New patent for this product
Pat. No. 10525033 [Img]
Use of amisulpride as an anti-emetic
Pat. Sub. Date(s): 001: Mar 16, 2020
Claim Types: Composition; Formulation
Mar 10, 2031New patent for this product

ENVARSUS XR (TABLET, EXTENDED RELEASE) (ORAL) TACROLIMUS
Drug Classes: calcineurin inhibitor immunosuppressant
NDA Applicant: VELOXIS PHARMS INC      NDA No.: 206406  Prod. No.: 001 RX (EQ 0.75MG BASE); 002 RX (EQ 1MG BASE); 003 RX (EQ 4MG BASE)
PatentsExpirationChange
Pat. No. 8664239 [Img]
Tacrolimus for improved treatment of transplant patients
Pat. Sub. Date(s): All strengths: Aug 24, 2015
Claim Types: Method of use
Use Code: U-1752: Prophylaxis of organ rejection
Use Code: U-2677: Prophylaxis of organ rejection in patients converted from tacrolimus immediate-release formulations
Use Code: U-2678: Prophylaxis of organ rejection in de novo transplant patient
Aug 30, 2028New expiration date. Was previously May 30, 2028; New Use Code
Pat. No. 8644239 DP* [Img]
Method and apparatus for allocating and processing sequences in communication system
Pat. Sub. Date(s): None
Claim Types: Patent number is typo. Claims an electronic communication method and system. Correct patent is ikely 8,664,239 which is assigned to NDA holder, and claims the approved indication.
Use Code: U-2677: Prophylaxis of organ rejection in patients converted from tacrolimus immediate-release formulations
Use Code: U-2678: Prophylaxis of organ rejection in de novo transplant patient
Aug 30, 2028This patent is no longer listed for this product

FABIOR (AEROSOL, FOAM) (TOPICAL) TAZAROTENE
Drug Classes: retinoid
NDA Applicant: MAYNE PHARMA      NDA No.: 202428  Prod. No.: 001 RX (0.1%)
PatentsExpirationChange
Pat. No. 10568859 [Img]
Topical foam composition
Pat. Sub. Date(s): 001: Mar 25, 2020
Claim Types: Formulation; Method of use
Use Code: U-2760: Topical treatment of acne vulgaris in patients 12 years of age or older
Feb 24, 2030New patent for this product

IMVEXXY (INSERT) (VAGINAL) ESTRADIOL
Drug Classes: estrogen
NDA Applicant: THERAPEUTICSMD INC      NDA No.: 208564  Prod. No.: 001 RX (0.004MG); 002 RX (0.01MG)
PatentsExpirationChange
Pat. No. 10568891 [Img]
Vaginal inserted estradiol pharmaceutical compositions and methods
Pat. Sub. Date(s): All strengths: Mar 19, 2020
Claim Types: Method of use
Use Code: U-2316: Treatment of dyspareunia
Use Code: U-2317: Treatment of a symptom of vulvar and vaginal atrophy
Jun 18, 2033New patent for this product

JEVTANA KIT (SOLUTION) (INTRAVENOUS) CABAZITAXEL
Drug Classes: microtubule inhibitor
NDA Applicant: SANOFI AVENTIS US      NDA No.: 201023  Prod. No.: 001 RX (60MG/1.5ML (40MG/ML))
PatentsExpirationChange
Pat. No. 10583110 [Img]
Antitumoral use of cabazitaxel
Pat. Sub. Date(s): 001: Mar 17, 2020
Claim Types: Method of use
Use Code: U-2753: Increasing survival in metastatic castration-resistant prostate cancer patients previously treated with docetaxel by administering as a 3 week cycle cabazitaxel after 5 mg dexchlorpheniramine, 8 mg dexamethasone, and an H2-agonist
Oct 27, 2030New patent for this product

LOTEMAX SM (GEL) (OPHTHALMIC) LOTEPREDNOL ETABONATE
Drug Classes: corticosteroid
NDA Applicant: BAUSCH AND LOMB INC      NDA No.: 208219  Prod. No.: 001 RX (0.38%)
PatentsExpirationChange
Pat. No. 10596107 [Img]
Ophthalmic suspension composition
Pat. Sub. Date(s): 001: Mar 31, 2020
Claim Types: Formulation; Method of use
Use Code: U-2764: Treatment of post-operative inflammation and pain following ocular surgery
Dec 23, 2036New patent for this product

NURTEC ODT (TABLET, ORALLY DISINTEGRATING) (ORAL) RIMEGEPANT SULFATE
NDA Applicant: BIOHAVEN PHARM      NDA No.: 212728  Prod. No.: 001 RX (EQ 75MG BASE)
PatentsExpirationChange
Pat. No. 8314117 [Img]
CGRP receptor antagonists
Pat. Sub. Date(s): 001: Mar 25, 2020
Claim Types: Compound; Composition; Method of use
Use Code: U-2718: Acute treatment of migraine with or without aura in adults
Feb 22, 2031New patent for this product
Pat. No. 8759372 [Img]
N-(5S,6S,9R)-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-ctclohepta- [b]Pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-carboxylate salt
Pat. Sub. Date(s): 001: Mar 25, 2020
Claim Types: New polymorph, salt or hydrate; Composition
Feb 25, 2033New patent for this product

PROAIR DIGIHALER (POWDER, METERED) (INHALATION) ALBUTEROL SULFATE
Drug Classes: beta-2 adrenergic agonist
NDA Applicant: TEVA BRANDED PHARM      NDA No.: 205636  Prod. No.: 002 RX (EQ 0.09MG BASE/INH)
PatentsExpirationChange
Pat. No. 10561808 [Img]
Dose counter for inhaler having an anti-reverse rotation actuator
Pat. Sub. Date(s): 002: Mar 19, 2020
Claim Types: Part of a dosage form
Jan 1, 2032New patent for this product
Pat. No. 10569034 [Img]
Compliance monitoring module for a breath-actuated inhaler
Pat. Sub. Date(s): 002: Mar 12, 2020
Claim Types: Device; Method of administration
Aug 16, 2036New patent for this product

PROAIR HFA (AEROSOL, METERED) (INHALATION) ALBUTEROL SULFATE [GENERIC AB]
Drug Classes: beta-2 adrenergic agonist
NDA Applicant: TEVA BRANDED PHARM      NDA No.: 021457  Prod. No.: 001 RX (EQ 0.09MG BASE/INH)
PatentsExpirationChange
Pat. No. 10561808 [Img]
Dose counter for inhaler having an anti-reverse rotation actuator
Pat. Sub. Date(s): 001: Mar 19, 2020
Claim Types: Part of a dosage form
Jan 1, 2032New patent for this product

PROCYSBI (GRANULE) (ORAL) CYSTEAMINE BITARTRATE
Drug Classes: cystine depleting agent
NDA Applicant: HORIZON PHARMA USA      NDA No.: 213491  Prod. No.: 001 RX (EQ 75MG BASE/PACKET); 002 RX (EQ 300MG BASE/PACKET)
PatentsExpirationChange
Pat. No. 8026284 [Img]
Enterically coated cystamine, cysteamine and derivatives thereof
Pat. Sub. Date(s): All strengths: Mar 13, 2020
Claim Types: Method of use; Method of administration
Use Code: U-1399: Management of nephropathic cystinosis by administering a total daily dose in two divided doses
Sep 22, 2027New patent for this product
Pat. No. 9173851 [Img]
Delayed release cysteamine bead formulation, and methods of making and using same
Pat. Sub. Date(s): All strengths: Mar 13, 2020
Claim Types: Formulation
Jun 17, 2034New patent for this product
Pat. No. 9173851 DP* [Img]
Delayed release cysteamine bead formulation, and methods of making and using same
Pat. Sub. Date(s): All strengths: Mar 13, 2020
Claim Types: Formulation
Jun 17, 2034New patent for this product
Pat. No. 9192590 [Img]
Enterically coated cysteamine, cystamine and derivatives thereof
Pat. Sub. Date(s): All strengths: Mar 13, 2020
Claim Types: Method of use
Use Code: U-1399: Management of nephropathic cystinosis by administering a total daily dose in two divided doses
Jan 26, 2027New patent for this product
Pat. No. 9198882 [Img]
Enterically coated cysteamine, cystamine and derivatives thereof
Pat. Sub. Date(s): All strengths: Mar 13, 2020
Claim Types: Method of use
Use Code: U-1399: Management of nephropathic cystinosis by administering a total daily dose in two divided doses
Jan 26, 2027New patent for this product
Pat. No. 9233077 [Img]
Delayed release cysteamine bead formulation, and methods of making and using same
Pat. Sub. Date(s): All strengths: Mar 13, 2020
Claim Types: Formulation
Jun 17, 2034New patent for this product
Pat. No. 9233077 DP* [Img]
Delayed release cysteamine bead formulation, and methods of making and using same
Pat. Sub. Date(s): All strengths: Mar 13, 2020
Claim Types: Formulation
Jun 17, 2034New patent for this product
Pat. No. 9925156 [Img]
Enterically coated cysteamine, cystamine and derivatives thereof
Pat. Sub. Date(s): All strengths: Mar 13, 2020
Claim Types: Formulation; Method of use
Use Code: U-1399: Management of nephropathic cystinosis by administering a total daily dose in two divided doses
Use Code: U-1399: Management of nephropathic cystinosis by administering a total daily dose in two divided doses
Jan 26, 2027New patent for this product
Pat. No. 9925157 [Img]
Enterically coated cysteamine, cystamine and derivatives thereof
Pat. Sub. Date(s): All strengths: Mar 13, 2020
Claim Types: Formulation; Method of use
Use Code: U-1399: Management of nephropathic cystinosis by administering a total daily dose in two divided doses
Use Code: U-1399: Management of nephropathic cystinosis by administering a total daily dose in two divided doses
Jan 26, 2027New patent for this product
Pat. No. 9925158 [Img]
Enterically coated cysteamine, cystamine and derivatives thereof
Pat. Sub. Date(s): All strengths: Mar 13, 2020
Claim Types: Formulation; Method of use
Use Code: U-1399: Management of nephropathic cystinosis by administering a total daily dose in two divided doses
Use Code: U-1399: Management of nephropathic cystinosis by administering a total daily dose in two divided doses
Jan 26, 2027New patent for this product
Pat. No. 10143665 [Img]
Methods for storing cysteamine formulations and related methods of treatment
Pat. Sub. Date(s): All strengths: Mar 13, 2020
Claim Types: Method of use
Use Code: U-1399: Management of nephropathic cystinosis by administering a total daily dose in two divided doses
Aug 16, 2036New patent for this product
Pat. No. 10328037 [Img]
Methods for storing cysteamine formulations and related methods of treatment
Pat. Sub. Date(s): All strengths: Mar 13, 2020
Claim Types: Method of use (with 3rd-party storage limitations)
Use Code: U-1399: Management of nephropathic cystinosis by administering a total daily dose in two divided doses
Aug 16, 2036New patent for this product
Pat. No. 10548859 [Img]
Methods for storing Cysteamine formulations and related methods of treatment
Pat. Sub. Date(s): All strengths: Mar 13, 2020
Claim Types: Method of use
Use Code: U-1399: Management of nephropathic cystinosis by administering a total daily dose in two divided doses
Aug 16, 2036New patent for this product

QVAR 80; QVAR 40 (AEROSOL, METERED) (INHALATION) BECLOMETHASONE DIPROPIONATE
Drug Classes: corticosteroid
NDA Applicant: TEVA BRANDED PHARM      NDA No.: 020911  Prod. No.: 001 DISC (0.08MG/INH**); 002 DISC (0.04MG/INH**)
PatentsExpirationChange
Pat. No. 10561808 [Img]
Dose counter for inhaler having an anti-reverse rotation actuator
Pat. Sub. Date(s): All strengths: Mar 19, 2020
Claim Types: Part of a dosage form
Jan 1, 2032New patent for this product

QVAR REDIHALER (AEROSOL, METERED) (INHALATION) BECLOMETHASONE DIPROPIONATE
Drug Classes: corticosteroid
NDA Applicant: NORTON WATERFORD      NDA No.: 207921  Prod. No.: 001 RX (0.04MG/INH); 002 RX (0.08MG/INH)
PatentsExpirationChange
Pat. No. 10561808 [Img]
Dose counter for inhaler having an anti-reverse rotation actuator
Pat. Sub. Date(s): All strengths: Mar 19, 2020
Claim Types: Part of a dosage form
Jan 1, 2032New patent for this product

REYVOW (TABLET) (ORAL) LASMIDITAN SUCCINATE
NDA Applicant: ELI LILLY AND CO      NDA No.: 211280  Prod. No.: 001 RX (50MG); 002 RX (100MG)
PatentsExpirationChange
Pat. No. 7423050 [Img]
Pyridinoylpiperidines as 5-HT.sub.1F agonists
Pat. Sub. Date(s): All strengths: Feb 25, 2020
Claim Types: Compound; Composition; Method of use
Use Code: U-1719: Acute treatment of migraine
Apr 6, 2025New patent for this product
Pat. No. 8748459 [Img]
Pyridinoylpiperidines as 5-HT.sub.1F agonists
Pat. Sub. Date(s): All strengths: Feb 25, 2020
Claim Types: Method of use
Use Code: U-1719: Acute treatment of migraine
Mar 27, 2023New patent for this product

RHOPRESSA (SOLUTION/DROPS) (OPHTHALMIC) NETARSUDIL MESYLATE
Drug Classes: Rho kinase inhibitor
NDA Applicant: AERIE PHARMS INC      NDA No.: 208254  Prod. No.: 001 RX (EQ 0.02% BASE)
PatentsExpirationChange
Pat. No. 10532993 [Img]
Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Pat. Sub. Date(s): 001: Mar 30, 2020
Claim Types: Method of use
Use Code: U-1524: Reduction of elevated intraocular pressure
Jul 11, 2026New patent for this product

ROCKLATAN (SOLUTION/DROPS) (OPHTHALMIC) LATANOPROST; NETARSUDIL DIMESYLATE
Drug Classes: prostaglandin analog; Rho kinase inhibitor
NDA Applicant: AERIE PHARMS INC      NDA No.: 208259  Prod. No.: 001 RX (0.005%;EQ 0.02% BASE)
PatentsExpirationChange
Pat. No. 10532993 [Img]
Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Pat. Sub. Date(s): 001: Mar 30, 2020
Claim Types: Method of use
Use Code: U-1524: Reduction of elevated intraocular pressure
Jul 11, 2026New patent for this product

ROZLYTREK (CAPSULE) (ORAL) ENTRECTINIB
NDA Applicant: GENENTECH INC      NDA No.: 212725  Prod. No.: 001 RX (100MG); 002 RX (200MG)
PatentsExpirationChange
Pat. No. 10561651 [Img]
Methods for treating neuroblastoma
Pat. Sub. Date(s): All strengths: Mar 13, 2020
Claim Types: Method of use
Use Code: U-2745: Treatment of neuroblastomas that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion
Feb 19, 2035New patent for this product

SECUADO (SYSTEM) (TRANSDERMAL) ASENAPINE
Drug Classes: atypical antipsychotic
NDA Applicant: HISAMITSU      NDA No.: 212268  Prod. No.: 001 RX (3.8MG/24HR); 002 RX (5.7MG/24HR); 003 RX (7.6MG/24HR)
PatentsExpirationChange
Pat. No. 10583121 [Img]
Patch
Pat. Sub. Date(s): All strengths: Mar 27, 2020
Claim Types: Device; Method of use
Use Code: U-2763: Method of treating adults with schizophrenia comprising administering asenapine via a transdermal patch
Jul 25, 2033New patent for this product

SOTALOL HYDROCHLORIDE (SOLUTION) (INTRAVENOUS) SOTALOL HYDROCHLORIDE
Drug Classes: antiarrhythmic
NDA Applicant: ALTATHERA PHARMS LLC      NDA No.: 022306  Prod. No.: 001 RX (150MG/10ML (15MG/ML))
PatentsExpirationChange
Pat. No. 10512620 [Img]
Method of initiating and escalating sotalol hydrochloride dosing
Pat. Sub. Date(s): 001: Mar 26, 2020
Claim Types: Method of use
Use Code: U-2769: Dosing regimen for intravenous sotalol for administration in a facility that can provide continuous electrocardiographic monitoring and cardiac resuscitation.
Aug 18, 2038New patent for this product

SUBLOCADE (SOLUTION, EXTENDED RELEASE) (SUBCUTANEOUS) BUPRENORPHINE
Drug Classes: partial opioid agonist
NDA Applicant: INDIVIOR INC      NDA No.: 209819  Prod. No.: 001 RX (100MG/0.5ML (100MG/0.5ML)); 002 RX (300MG/1.5ML (200MG/ML))
PatentsExpirationChange
Pat. No. 10592168 [Img]
Injectable flowable composition comprising buprenorphine
Pat. Sub. Date(s): All strengths: Mar 19, 2020
Claim Types: Method of use
Use Code: U-2489: Treatment of moderate to severe opioid use disorder
Jun 6, 2031New patent for this product

TOSYMRA (SPRAY) (NASAL) SUMATRIPTAN
Drug Classes: serotonin 5-HT1B/1D receptor agonist (triptan)
NDA Applicant: UPSHER SMITH LABS      NDA No.: 210884  Prod. No.: 001 RX (10MG/SPRAY)
PatentsExpirationChange
Pat. No. 10603305 [Img]
Formulations comprising triptan compounds
Pat. Sub. Date(s): 001: Mar 31, 2020
Claim Types: Formulation; Method of use
Use Code: U-1719: Acute treatment of migraine
Jun 16, 2030New patent for this product

VABOMERE (POWDER) (INTRAVENOUS) MEROPENEM; VABORBACTAM
Drug Classes: penem antibacterial; beta lactamase inhibitor
NDA Applicant: REMPEX PHARMS      NDA No.: 209776  Prod. No.: 001 RX (1GM/VIAL;1GM/VIAL)
PatentsExpirationChange
Pat. No. 10561675 [Img]
Cyclic boronic acid ester derivatives and therapeutic uses thereof
Pat. Sub. Date(s): 001: Mar 18, 2020
Claim Types: Method of use
Use Code: U-2490: Treatment of complicated urinary tract infection (CUTI) including pyelonephritis caused by the following susceptible microorganisms: escherichia coli, klebsiella pneumonia, and enterobacter cloacae species complex
Aug 8, 2031New patent for this product

VASCEPA (CAPSULE) (ORAL) ICOSAPENT ETHYL
NDA Applicant: AMARIN PHARMS      NDA No.: 202057  Prod. No.: 001 RX (1GM); 002 RX (500MG)
PatentsExpirationChange
Pat. No. 8518929 [Img]
Methods of treating hypertriglyceridemia
Pat. Sub. Date(s): 001: None; 002: Jun 26, 2017
Claim Types: Method of use
Use Code: U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
Feb 9, 2030New expiration date. Was previously Apr 29, 2030
Pat. No. 8524698 [Img]
Methods of treating hypertriglyceridemia
Pat. Sub. Date(s): 001: Sep 11, 2013; 002: Jun 26, 2017
Claim Types: Method of administration
Use Code: U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
Feb 9, 2030New expiration date. Was previously Apr 29, 2030
Pat. No. 8546372 [Img]
Methods of treating hypertriglyceridemia
Pat. Sub. Date(s): 001: Oct 1, 2013; 002: Jun 26, 2017
Claim Types: Method of use
Use Code: U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
Feb 9, 2030New expiration date. Was previously Apr 29, 2030
Pat. No. 10568861 [Img]
Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
Pat. Sub. Date(s): All strengths: Mar 20, 2020
Claim Types: Method of use
Use Code: U-2756: Use of VASCEPA as an adjunct to statin therapy to reduce the risk of cardiovascular death in an adult patient with established cardiovascular disease
Jun 28, 2033New patent for this product
Pat. No. 10576054 [Img]
Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
Pat. Sub. Date(s): All strengths: Mar 27, 2020
Claim Types: Method of use
Use Code: U-2762: Use of VASCEPA as an adjunct to statin therapy to reduce the risk of a major cardiovascular event in an adult patient with diabetes mellitus and two or more additional risk factors for cardiovascular disease
Jun 28, 2033New patent for this product

XEPI (CREAM) (TOPICAL) OZENOXACIN
Drug Classes: quinolone antimicrobial
NDA Applicant: FERRER INTERNACIONAL      NDA No.: 208945  Prod. No.: 001 RX (1%)
PatentsExpirationChange
Pat. No. 6335447 DS* [Img]
Quinolonecarboxylic acid derivatives or salts thereof
Pat. Sub. Date(s): 001: Jan 19, 2018
Claim Types: Compound
Apr 6, 2021New expiration date. Was previously Apr 6, 2020


DS*=Drug Substance and DP*=Drug Product: patent submitted for the product after Aug. 18, 2003.
** Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons
Last edited: 16 April 2020
© 2001-2020 Bruce A. Pokras, All rights reserved worldwide